🚨BREAKING!! $NVO
Stock is up +6.2% in after hours!
Novo Nordisk $NVO has received FDA approval for Wegovy® (semaglutide) 2.4 mg injection to treat adults with noncirrhotic MASH (metabolic dysfunction-associated steatohepatitis) with moderate to advanced liver fibrosis.
This marks a significant milestone as Wegovy® becomes the first GLP-1 RA approved for MASH treatment.
The approval is based on the Phase 3 ESSENCE trial results, which showed that 63% of Wegovy®-treated patients achieved steatohepatitis resolution compared to 34% on placebo, and 37% showed liver fibrosis improvement versus 22% on placebo.
The drug demonstrated strong efficacy with 83.5% of patients maintaining the target dose through Week 72.
This represents Wegovy's fourth FDA-approved indication, following its previous approvals for obesity management, cardiovascular risk reduction, and pediatric obesity treatment.
Novo Nordisk has also submitted regulatory applications in the EU and Japan.
Get access to Nordic Bulls multi-factor ranking and selection system that continuously evaluates thousands of stocks across the U.S. market
$QQQ $SPY
https://t.co/ueLeYBr562
Ready to level up your trading process?
Nordic Bulls is launched on Patreon. It gives you disciplined, “quantamental” ideas without the noise. 4+ high-conviction picks/month
Start here → https://t.co/eElbHTvaj0
#NordicBulls#Investing#investering $SPY $QQQ
$NVO Semaglutide, active ingredient of Wegovy and Ozempic, found to reduce cravings and cut drinking by 40%.
This could be a new industry for Novo Nordisk .
https://t.co/teKtMkTL8n